Literature DB >> 6114171

Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.

E J Sybertz, C S Sabin, K K Pula, G V Vliet, J Glennon, E H Gold, T Baum.   

Abstract

Labetalol is a mixture of four isomers. Its alpha and beta adrenergic blocking properties were compared to those of the R,R-isomer, SCH 19927. In anesthetized dogs, i.v. administration of both compounds produced competitive beta and alpha blockade as judged by inhibition of the tachycardia and vasopressor responses to i.v. injections of isoproterenol and phenylpherine, respectively. SCH 19927 was 3 to 4 times as potent as beta blocker, but only one-third as potent an alpha blocker as labetalol. Therefore, the separation of beta and alpha blocking activity of SCH 19927 clearly exceeded that of labetalol. SCH 19927 also demonstrated greater beta blocking potency than labetalol after oral administration to conscious dogs or rats that were subsequently pithed. SCH 19927 did not affect, whereas labetalol slightly reduced, pressor responses to sympathetic stimulation in the pithed rat. Both drugs were relatively devoid of intrinsic beta-1 sympathomimetic activity in the ganglion-blocked dog. It is concluded that SCH 19927 is a more potent beta adrenoceptor blocker and less potent alpha blocker than labetalol. The separation of adrenergic blocker activities indicates that steric requirements for alpha and beta blockade differ in the labetalol molecule.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6114171

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?

Authors:  W M Blankesteijn; S J Graafsma; M P Hectors; E A Olde Riekerink; J F Rodrigues de Miranda; T Thien
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Impact of dilevalol on haemodynamic changes during emotional stress.

Authors:  H Rüddel; W Langewitz; M Bähr; M Düsterwald; H Schächinger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.

Authors:  P A van Zwieten
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

4.  Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension.

Authors:  T Baba; S Murabayashi; K Aoyagi; T Ishizaki
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 6.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers.

Authors:  E Riva; T Mennini; R Latini
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

8.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients.

Authors:  T Walley; Y Tsao; A Scott; E Mackay; M Vandenburg; A Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1993-06       Impact factor: 4.335

10.  Comparison of medroxalol and labetalol, drugs with combined alpha- and beta-adrenoceptor antagonist properties.

Authors:  H L Elliott; K McLean; P A Meredith; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.